No Data
No Data
Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Janux Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $63
Buy Rating Affirmed for Janux Therapeutics With Revised Higher Price Target Amidst Strong Financials and Promising Clinical Trials
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on Janux Therapeutics, Maintains $100 Price Target
We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate
No Data